Abstract
A 9-year-old girl with severe refractory aplastic anemia had become refractory to platelet transfusion due to platelet alloimmunization. As a result, a huge right parieto-temporo-occipital cerebral hematoma and a subarachnoid hemorrhage subsequently occurred. Intravenous immunoglobulin (IVIG) (Green Cross, Taiwan) at a dose of 0.4 g/kg/day for 5 days, followed by another 3 doses during the following 5 days, and combined with large-dose platelet transfusions effectively controlled the bleeding by elevating the platelet count to above 100 x 103/mm3. The patient soon recovered with only a mild sequela. Two months later, because of multiple caries and a periodontal abscess, dental extraction needed to be performed. IVIG (0.4 g/kg/day x 6 days) enabled surgery to proceed by elevating the platelet count to above 55 x 103/mm3, and no bleeding complications occurred during or after the procedure. The potential benefit of high-dose IVIG in modulating platelet alloimmunization is a result of increasing the survival of transfused platelets. Thus, this therapy is recommended when patients with platelet alloimmunization have critical bleeding episodes or undergo surgical procedures.
| Original language | English |
|---|---|
| Pages (from-to) | 165-166 |
| Number of pages | 2 |
| Journal | American Journal of Hematology |
| Volume | 49 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - 1995 |
| Externally published | Yes |
Fingerprint
Keywords
- Aplastic anemia
- Intracranial hemorrhage
- IVIG
- Platelet alloimmunization
ASJC Scopus subject areas
- Hematology
Cite this
Treatment of platelet alloimmunization with intravenous immunoglobulin in a child with aplastic anemia. / Chen, S. H.; Liang, D. C.; Lin, M.
In: American Journal of Hematology, Vol. 49, No. 2, 1995, p. 165-166.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Treatment of platelet alloimmunization with intravenous immunoglobulin in a child with aplastic anemia
AU - Chen, S. H.
AU - Liang, D. C.
AU - Lin, M.
PY - 1995
Y1 - 1995
N2 - A 9-year-old girl with severe refractory aplastic anemia had become refractory to platelet transfusion due to platelet alloimmunization. As a result, a huge right parieto-temporo-occipital cerebral hematoma and a subarachnoid hemorrhage subsequently occurred. Intravenous immunoglobulin (IVIG) (Green Cross, Taiwan) at a dose of 0.4 g/kg/day for 5 days, followed by another 3 doses during the following 5 days, and combined with large-dose platelet transfusions effectively controlled the bleeding by elevating the platelet count to above 100 x 103/mm3. The patient soon recovered with only a mild sequela. Two months later, because of multiple caries and a periodontal abscess, dental extraction needed to be performed. IVIG (0.4 g/kg/day x 6 days) enabled surgery to proceed by elevating the platelet count to above 55 x 103/mm3, and no bleeding complications occurred during or after the procedure. The potential benefit of high-dose IVIG in modulating platelet alloimmunization is a result of increasing the survival of transfused platelets. Thus, this therapy is recommended when patients with platelet alloimmunization have critical bleeding episodes or undergo surgical procedures.
AB - A 9-year-old girl with severe refractory aplastic anemia had become refractory to platelet transfusion due to platelet alloimmunization. As a result, a huge right parieto-temporo-occipital cerebral hematoma and a subarachnoid hemorrhage subsequently occurred. Intravenous immunoglobulin (IVIG) (Green Cross, Taiwan) at a dose of 0.4 g/kg/day for 5 days, followed by another 3 doses during the following 5 days, and combined with large-dose platelet transfusions effectively controlled the bleeding by elevating the platelet count to above 100 x 103/mm3. The patient soon recovered with only a mild sequela. Two months later, because of multiple caries and a periodontal abscess, dental extraction needed to be performed. IVIG (0.4 g/kg/day x 6 days) enabled surgery to proceed by elevating the platelet count to above 55 x 103/mm3, and no bleeding complications occurred during or after the procedure. The potential benefit of high-dose IVIG in modulating platelet alloimmunization is a result of increasing the survival of transfused platelets. Thus, this therapy is recommended when patients with platelet alloimmunization have critical bleeding episodes or undergo surgical procedures.
KW - Aplastic anemia
KW - Intracranial hemorrhage
KW - IVIG
KW - Platelet alloimmunization
UR - http://www.scopus.com/inward/record.url?scp=0029004809&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029004809&partnerID=8YFLogxK
U2 - 10.1002/ajh.2830490213
DO - 10.1002/ajh.2830490213
M3 - Article
C2 - 7771471
AN - SCOPUS:0029004809
VL - 49
SP - 165
EP - 166
JO - American Journal of Hematology
JF - American Journal of Hematology
SN - 0361-8609
IS - 2
ER -